Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Par Pharmaceutical Companies
Par Pharmaceutical Companies
Activities:
Manufacturing
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Endo to purchase Par Pharmaceutical for US$8.05bn
Expanding generics business, product portfolio, pipeline and manufacturing capabilities
Manufacturing
Par Pharmaceutical to buy JHP Pharmaceuticals
Adds sterile injectable products to its portfolio
Finance
Par Pharmaceutical agrees to be acquired by private equity
US generics firm will continue to seek other buyers
Pharmaceutical
Par Pharmaceutical makes two promotions
To manage the expanded company and its subsidiaries
Finance
Par Pharmaceutical completes acquisition of Anchen
Purchase brings five commercialised products and 27 ANDAs on file with the US FDA
Finance
Par Pharmaceutical to pay US$410m for Anchen
Second acquisition of a privately held generics manufacturer this year
Finance
Par Pharmaceutical to acquire Edict Pharmaceuticals in India
Strengthens r&d and adds manufacturing capacity
Subscribe now